<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086748</url>
  </required_header>
  <id_info>
    <org_study_id>11958</org_study_id>
    <secondary_id>H8Y-MC-HBBM</secondary_id>
    <nct_id>NCT01086748</nct_id>
  </id_info>
  <brief_title>A Study in Schizophrenia Patients</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill&#xD;
      patients with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score in overall schizophrenia population</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>A change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score in a genetic subgroup of schizophrenia patients</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in the Personal and Social Performance (PSP) score in the overall schizophrenia population</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in the Personal and Social Performance (PSP) score in a genetic subgroup of schizophrenia patients</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in the PANSS positive scale</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in the PANSS negative scale</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in PANSS General Psychopathology subscale</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in the Clinical Global Impression-Severity Scale (CGI-S)</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in the 16-item Negative Symptoms Assessment (NSA-16)</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in the Montgomery-Çºsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS total score</measure>
    <time_frame>up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score in a female patients</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of discontinuation</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline on the EuroQol - 5 Dimensions (EQ-5D) Questionnaire</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline on resource utilization, as measured by the Schizophrenia Resource Use Model (S-RUM)</measure>
    <time_frame>Baseline up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline on functional capacity, as measured by the Subjective Well-Being Under Neuroleptic Treatment Scale - Short Form (SWN-S)</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in Barnes Akathisia Scale (BAS)</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in Simpson-Angus Scale (SAS)</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A mean change from baseline in Prolactin levels</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in weight</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram parameters</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in neurological examination</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically different changes in vital signs from baseline</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically different changes in lab values from baseline</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetics (PK) of LY2140023</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in Columbia- Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>baseline, up to 7 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">880</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>160 mg LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mg risperidone administered orally, BID for up to 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally, BID for up to 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg LY2140023 administered orally, BID for up to 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>4 mg Risperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>160 mg LY2140023</arm_group_label>
    <arm_group_label>80 mg LY2140023</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of schizophrenia as defined in the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR; APA 2000) (Disorganized,&#xD;
             295.10; Catatonic, 295.20; Paranoid 295.30; or Undifferentiated, 295.90) and confirmed&#xD;
             by the Structured Clinical Interview for DSM-IV-TR (SCID).&#xD;
&#xD;
          -  Non pregnant female patients who agree to use acceptable birth control&#xD;
&#xD;
          -  At entry to the study must be considered moderately ill in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Willing to participate in a minimum of 3 weeks of inpatient hospitalization and this&#xD;
             must be appropriate for the patient in the clinical judgment of the investigator.&#xD;
&#xD;
          -  1 year history of Schizophrenia prior to entering the study&#xD;
&#xD;
          -  At study entry patients with a history of antipsychotic treatment must have a lifetime&#xD;
             history of at least one hospitalization for the treatment of schizophrenia, not&#xD;
             including the hospitalization required for study. Patients who have never taken&#xD;
             antipsychotic treatment may enter the study even without a history of hospitalization.&#xD;
&#xD;
          -  At study entry patients with a history of antipsychotic treatment must have a history&#xD;
             of at least one episode of illness exacerbation requiring an intensification of&#xD;
             treatment intervention or care in the last 2 years, not including the present episode&#xD;
             of illness. Patients who have never taken antipsychotic treatment may enter the study&#xD;
             without a past history of illness exacerbation and intensification of treatment in the&#xD;
             last 2 years.&#xD;
&#xD;
          -  At study entry patients must have experienced an exacerbation of illness within the 2&#xD;
             weeks prior to entering the study, leading to an intensification of psychiatric care&#xD;
             in the opinion of the investigator. If exacerbation occurs in patients who are&#xD;
             presently hospitalized, the patient must not have been hospitalized longer than 60&#xD;
             days at entry of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participated in any clinical trial with any pharmacological treatment intervention for&#xD;
             which they received a study-related medication in the 6 months prior to visit 1&#xD;
&#xD;
          -  Previously completed or withdrawn from this study, or any other study investigating&#xD;
             LY2140023 or any predecessor molecules with glutamatergic activity.&#xD;
&#xD;
          -  Treatment with clozapine at doses greater than 200 mg daily within 12 months prior to&#xD;
             entering the study, or who have received any clozapine at all during the month before&#xD;
             entering the study&#xD;
&#xD;
          -  Patients currently receiving treatment (within 1 dosing interval, minimum of 4 weeks,&#xD;
             prior entering the study) with a depot formulation of an antipsychotic medication.&#xD;
&#xD;
          -  Patients who are currently suicidal.&#xD;
&#xD;
          -  Females who are pregnant, nursing, or who intend to become pregnant within 30 days of&#xD;
             completing the study.&#xD;
&#xD;
          -  Patients with uncorrected narrow-angle glaucoma, uncontrolled diabetes, certain&#xD;
             diseases of the liver, renal insufficiency, uncontrolled thyroid condition or other&#xD;
             serious or unstable illnesses&#xD;
&#xD;
          -  Have a history of one or more seizures, except for those who experienced a single&#xD;
             simple febrile seizure between ages 6 months and 5 years&#xD;
&#xD;
          -  Patients are excluded if their, biological father, mother, brother, sister, or child&#xD;
             has a history of idiopathic epilepsy.&#xD;
&#xD;
          -  Within 1 year of study enrollment, patients have a history of central nervous system&#xD;
             infection, uncontrolled migraine, transient ischemic attack (TIA), or head trauma with&#xD;
             loss of consciousness or a post-concussive&#xD;
&#xD;
          -  Patients are excluded if they have a lifetime history of any of the following:&#xD;
&#xD;
               -  head trauma, stroke, or CNS infection with persistent neurological deficit (focal&#xD;
                  or diffuse);&#xD;
&#xD;
               -  brain surgery;&#xD;
&#xD;
               -  an electroencephalogram with paroxysmal (epileptiform) activity, or&#xD;
&#xD;
               -  brain structural lesion, including developmental abnormalities, as determined by&#xD;
                  examination or previous neuroimaging studies that are consistent with a&#xD;
                  diagnosable neurological disease or syndrome.&#xD;
&#xD;
          -  Electroconvulsive therapy (ECT) within 3 months of entering the study or who will have&#xD;
             ECT at any time during the study.&#xD;
&#xD;
          -  Leukopenia&#xD;
&#xD;
          -  Medical history of Human Immunodeficiency Virus positive (HIV+) status.&#xD;
&#xD;
          -  Higher than normal blood prolactin levels&#xD;
&#xD;
          -  Certain electrocardiogram results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zagreb</city>
        <zip>10090</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Khotkovo</city>
        <zip>127025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lipetsk</city>
        <zip>399007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Samara</city>
        <zip>443016</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <disposition_first_submitted>September 18, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 18, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 25, 2012</disposition_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 25, 2021</submitted>
    <returned>September 23, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

